Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
13.10
+0.64 (5.18%)
Apr 29, 2026, 9:16 AM EDT - Market open
Cue Biopharma Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 43 | 28 | 69 | 119 | 123 | 359 | |
| Market Cap Growth | -10.03% | -59.65% | -42.03% | -2.89% | -65.85% | -5.17% | |
| Enterprise Value | 17 | 14 | 46 | 81 | 83 | 295 | |
| Last Close Price | 12.46 | 9.16 | 32.70 | 79.20 | 85.50 | 339.30 | |
| PS Ratio | 1.48 | 1.01 | 7.44 | 21.70 | 98.53 | 24.04 | |
| PB Ratio | 1.52 | 1.05 | 3.95 | 3.21 | 1.87 | 5.49 | |
| P/TBV Ratio | 1.53 | 1.05 | 3.95 | 3.21 | 1.87 | 5.49 | |
| EV/Sales Ratio | 0.60 | 0.50 | 4.97 | 14.72 | 66.75 | 19.76 | |
| Debt / Equity Ratio | 0.16 | 0.16 | 0.51 | 0.40 | 0.29 | 0.15 | |
| Net Debt / Equity Ratio | -0.91 | -0.91 | -0.83 | -0.92 | -0.87 | -0.83 | |
| Net Debt / EBITDA Ratio | 0.94 | 0.94 | 0.35 | 0.66 | 1.08 | 1.28 | |
| Net Debt / FCF Ratio | 1.10 | 1.10 | 0.40 | 0.85 | 1.36 | 1.37 | |
| Asset Turnover | 0.74 | 0.74 | 0.20 | 0.07 | 0.01 | 0.16 | |
| Quick Ratio | 2.64 | 2.64 | 1.78 | 2.96 | 6.61 | 5.28 | |
| Current Ratio | 2.74 | 2.74 | 1.84 | 3.01 | 6.68 | 5.35 | |
| Return on Equity (ROE) | -121.11% | -121.11% | -149.03% | -98.73% | -80.82% | -61.16% | |
| Return on Assets (ROA) | -44.56% | -44.56% | -55.47% | -42.53% | -38.29% | -29.87% | |
| Return on Capital Employed (ROCE) | -92.30% | -92.30% | -224.80% | -117.00% | -67.10% | -61.90% | |
| Earnings Yield | -65.61% | -95.47% | -58.90% | -42.59% | -43.21% | -12.29% | |
| FCF Yield | -53.92% | -78.47% | -52.71% | -33.55% | -34.22% | -11.07% | |
| Buyback Yield / Dilution | -68.18% | -68.18% | -23.11% | -28.35% | -13.95% | -9.05% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.